An investigation on behalf of current long term investors in Johnson & Johnson (Public, NYSE:JNJ) in connection with possible violations of the U.S. Foreign Corrupt Practices Act was announced.

Johnson & Johnson, located in New Brunswick, NJ, is engaged in the research and development, manufacture and sale of a range of products in the health care field. According to the investigation by a law firm the investigation on behalf of current long term investors in Johnson & Johnson (Public, NYSE:JNJ) stocks focuses on potential violations of the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits companies from making improper payments to foreign officials for the purpose of obtaining or keeping business. According to the Justice Department The Foreign Corrupt Practices Act was enacted for the purpose of making it unlawful for certain classes of persons and entities to make payments to foreign government officials to assist in obtaining or retaining business. Specifically, the anti-bribery provisions of the FCPA prohibit the willful use of the mails or any means of instrumentality of interstate commerce corruptly in furtherance of any offer, payment, promise to payto a foreign official to influence the foreign official in his or her official capacity to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business to, any person.

Johnson & Johnson reported a Total Revenue of $53.324billion in 2006, $61.095billion in 2007, $63.747billion in 2008, and $61.897billion in 2009. Johnson & Johnson reported a Net Income of $11.053billion in 2006, $10.576billion in 2007, $12.949billion in 2008, and $12.266billion in 2009.

Nearly a dozen companies have already settled foreign bribery charges with prosecutors in a string of cases that started in 2002. Johnson & Johnson disclosed that in February 2006, it received a subpoena from the U.S. Securities & Exchange Commission requesting documents relating to the participation by several Johnson & Johnson subsidiaries in the United Nations Iraq Oil for Food Program. The subsidiaries are cooperating with the SEC and U.S. Department of Justice (DOJ) in producing responsive information.

Then in February 2007, Johnson & Johnson disclosed to the DOJ and the SEC that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries.

Shares of Johnson & Johnson (NYSE:JNJ) traded recently at $59.22 per share, down from its current 52weekHigh of $66.20 per share, and over $70 per share during 2008.